Merck KGaA Deal Gives Diaccurate New Lead Cancer Candidate
Biotech Targets Triple-Negative Breast Cancer and Lymphoma
The Paris-based biotech was chosen to take the compound forward, with Merck KGaA also taking a stake in the company.
You may also be interested in...
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.
Belén Garijo, the German group's CEO, has told analysts she considers targeted smaller to medium-sized acquisitions to be more likely than major transformational deals but said that "we are always open to something bolder."
Two companies looking to challenge Merck’s Keytruda with new combinations have had contrasting reactions from investors